What is the 13F Pro Quality Score for AGIO?

13F Pro ranks AGIOS PHARMACEUTICALS, INC. (AGIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AGIO's current score at https://13fpro.ai/company/AGIO (free sign-up required for the full ranking).

Which hedge funds own the most AGIO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AGIO include BlackRock,, FARALLON CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/AGIO as soon as new 13F filings post.

Where does 13F Pro source AGIO data?

All AGIOS PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. AGIOS PHARMACEUTICALS, INC. files with the SEC under CIK 1439222. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AGIO in?

AGIOS PHARMACEUTICALS, INC. (AGIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AGIO research updated on 13F Pro?

AGIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AGIOS PHARMACEUTICALS, INC.(AGIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1439222 AGIO stock profile & AI dashboard →

13F Pro Quality Score

26.9/100

Rank #2,598 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

96.0/100

Profitability

3.6/100

Balance Sheet

7.2/100

Earnings Quality

15.1/100

Free Cash Flow

3.1/100

Institutional Flow

35.4/100

Revenue Scale

15.4/100

Dilution Risk

3.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AGIO Scores 27/100

exact factor attribution · 2026-09-11

AGIO's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.2 pts

96th pct

Institutional flow

-0.7 pts

35th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.3 pts

3th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-4.3 pts

7th pct

Scale

-5.2 pts

15th pct

Profitability

-7.0 pts

4th pct

Free cash flow

-7.0 pts

3th pct

Latest change (2026-07-30): 26 → 26 · ↓ Institutional flow 54→46

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AGIO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for AGIOS PHARMACEUTICALS, INC. (AGIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AGIO at 26.9/100 on a 32-signal composite quality model, placing it at rank #2,598 of 2,962 stocks — the bottom half of the AI-ranked universe. AGIO scores in the top quartile across revenue growth (96.0). Areas of concern include free cash flow (3.1) and profitability (3.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AGIOS PHARMACEUTICALS, INC. reports quarterly revenue of $44.7M, net income of $-100.7M, free cash flow of $-58.5M. Top institutional holders of AGIO by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. AGIO trades on the Nasdaq exchange and files with the SEC under CIK 1439222. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AGIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AGIOS PHARMACEUTICALS, INC. directly from SEC EDGAR. AGIOS PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 26 and 65 since 2024, currently 26.9 — a declining long-term trajectory across 55 quarterly and live scoring snapshots.

✦

Fun facts about AGIOS PHARMACEUTICALS, INC.

Quirks, history, and lore behind AGIO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on cancer and rare diseases.
2
The Numbers
A small-cap biopharma with revenues in the low hundreds of millions — modest by pharma standards, but built on a handful of highly specialized drugs.
3
The History
Founded in 2008, it spun out of academic research and built its pipeline around cellular metabolism — the study of how cells make and use energy, particularly in cancer.
4
The Secret
Its drugs target mutant IDH enzymes — molecular culprits found in certain leukemias and other cancers — a mechanism most pharma giants overlooked for years.
5
The Lore
It sold its oncology business to Servier in a landmark deal, then reinvented itself around rare blood disorders like pyruvate kinase deficiency — a disease most doctors had never treated.
6
The Giveaway
Its approved drug mitapivat targets pyruvate kinase deficiency, and its ticker is a Greek word meaning something holy — fitting for a company hunting cures in the chemistry of life itself.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$44.7M

Net Income

Q2 2026

$-100.7M

Free Cash Flow

Q2 2026

$-58.5M

ROIC

Q2 2026

-43.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+48.0% YoY

$54.0MFY 2025

FY22 $14.2MFY23 $26.8MFY24 $36.5MFY25 $54.0M

Net Income

-161.3% YoY

$-412.8MFY 2025

FY22 $-231.8MFY23 $-352.1MFY24 $673.7MFY25 $-412.8M

Operating Income

-10.9% YoY

$-472.1MFY 2025

FY22 $-389.0MFY23 $-391.5MFY24 $-425.7MFY25 $-472.1M

EPS (Diluted)

-161.2% YoY

$-7.12FY 2025

FY22 $-4.23FY23 $-6.33FY24 $11.64FY25 $-7.12

Total Assets

-22.0% YoY

$1.30BFY 2025

FY22 $1.24BFY23 $937.1MFY24 $1.66BFY25 $1.30B

Op. Cash Flow

+4.3% YoY

$-373.0MFY 2025

FY22 $-309.5MFY23 $-296.1MFY24 $-389.8MFY25 $-373.0M

Free Cash Flow

+3.6% YoY

$-377.3MFY 2025

FY22 $-314.4MFY23 $-297.1MFY24 $-391.5MFY25 $-377.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$54.0M +48.0%	$36.5M +36.1%	$26.8M +88.4%	$14.2M	$0.00	$0.00
Net Income	$-412.8M -161.3%	$673.7M +291.4%	$-352.1M -51.9%	$-231.8M -114.4%	$1.60B +590.2%	$-327.4M
Operating Income	$-472.1M -10.9%	$-425.7M -8.7%	$-391.5M -0.6%	$-389.0M -2.8%	$-378.4M -12.7%	$-335.9M
EPS (Diluted)	$-7.12 -161.2%	$11.64 +283.9%	$-6.33 -49.6%	$-4.23 -115.9%	$26.55 +660.1%	$-4.74
Total Assets	$1.30B -22.0%	$1.66B +77.5%	$937.1M -24.3%	$1.24B -13.8%	$1.44B +68.6%	$853.0M
Operating Cash Flow	$-373.0M +4.3%	$-389.8M -31.7%	$-296.1M +4.3%	$-309.5M +24.0%	$-407.3M -40.1%	$-290.8M
Free Cash Flow	$-377.3M +3.6%	$-391.5M -31.8%	$-297.1M +5.5%	$-314.4M +23.9%	$-413.1M -35.5%	$-304.9M

Get alerted when AGIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AGIOS PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AGIO

BlackRock, Inc.
$239.6M6,455,997 sh
FARALLON CAPITAL MANAGEMENT LLC
$219.6M5,917,400 sh
STATE STREET CORP
$131.1M3,533,633 sh
Lynx1 Capital Management LP
$126.5M3,408,937 sh
D. E. Shaw & Co., Inc.
$115.3M3,107,005 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$107.6M2,898,197 sh
ARMISTICE CAPITAL, LLC
$104.3M2,810,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$99.5M2,681,845 sh
ARMISTICE CAPITAL, LLC
$89.1M2,400,000 sh
Erste Asset Management GmbH
$82.0M2,154,900 sh

Fund	Value	Shares
BlackRock, Inc.	$239.6M	6,455,997
FARALLON CAPITAL MANAGEMENT LLC	$219.6M	5,917,400
STATE STREET CORP	$131.1M	3,533,633
Lynx1 Capital Management LP	$126.5M	3,408,937
D. E. Shaw & Co., Inc.	$115.3M	3,107,005
VANGUARD PORTFOLIO MANAGEMENT LLC	$107.6M	2,898,197
ARMISTICE CAPITAL, LLC	$104.3M	2,810,000
VANGUARD CAPITAL MANAGEMENT LLC	$99.5M	2,681,845
ARMISTICE CAPITAL, LLC	$89.1M	2,400,000
Erste Asset Management GmbH	$82.0M	2,154,900

Companies Similar to AGIO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CRNX

Crinetics Pharmaceuticals, Inc.

AI score

Very similar · 13 shared holders

FARALLON CAPITAL MANAGEMENT LLC ADAR1 Capital Management, LLC KENNEDY CAPITAL MANAGEMENT LLC

CYTK

CYTOKINETICS INC

AI score

Very similar · 9 shared holders

ARMISTICE CAPITAL, LLC ADAR1 Capital Management, LLC Rock Springs Capital Management LP

CGON

CG Oncology, Inc.

AI score

Very similar · 10 shared holders

Foresite Capital Management VI LLC FARALLON CAPITAL MANAGEMENT LLC ADAR1 Capital Management, LLC

SNDX

Syndax Pharmaceuticals Inc

AI score

Very similar · 12 shared holders

Parkman Healthcare Partners LLC Palo Alto Investors LP Knott David M Jr

KURA

Kura Oncology, Inc.

AI score

Very similar · 12 shared holders

ARMISTICE CAPITAL, LLC Ishara Investments LP MARTINGALE ASSET MANAGEMENT L P

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Similar quality profile · 9 shared holders

Parkman Healthcare Partners LLC Caligan Partners LP Knott David M Jr

AUTL

Autolus Therapeutics plc

AI score

Similar quality profile · 6 shared holders

ARMISTICE CAPITAL, LLC TFG Asset Management GP Ltd Hennion & Walsh Asset Management, Inc.

BCYC

BICYCLE THERAPEUTICS PLC

AI score

Similar quality profile · 8 shared holders

ARMISTICE CAPITAL, LLC Palo Alto Investors LP Virtus Investment Advisers, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AGIO on your watchlist

Track score changes the day AGIOS PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AGIO a good stock to buy?

13F Pro's AI-powered analysis of AGIOS PHARMACEUTICALS, INC. (AGIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AGIO are available on the AGIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AGIO is classified as a mid company.

Which hedge funds own AGIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AGIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AGIOS PHARMACEUTICALS, INC.'s investment landscape.